Check out the list of speakers for Partnering for Cures! | Investigate the latest trends in consortia research with the Power of Collaboration series | Company to test peptide against metastatic breast cancer
A mutation in the OTULIN gene that results in improper processing of the protein ubiquitin causes a rare inflammatory disease in children called otulipenia that can be treated with anti-tumor necrosis factor inhibitors, NIH researchers reported in Proceedings of the National Academy of Sciences. "This discovery suggests a direction that can be explored for development of new therapies for patients with a wide range of inflammatory diseases," scientist Ivona Aksentijevich said.
The list of Partnering for Cures speakers is growing. Check out this great lineup Nov. 13 to 15 in New York! Partnering for Cures brings together hundreds of decision-makers from across diseases who are motivated by the same mission: to reduce the time and cost of getting new therapies from discovery to patients. More details will be added throughout the summer.
FasterCures' Consortia-pedia Catalogue has increased from 369 consortia in 2014 to nearly 500 today. In our latest Power of Collaboration blog post, we explore how the consortia field has evolved, grown and changed. This blog series explores how collaborations have been working to change the nature of biomedical research.
A peptide called CT20 discovered in 2012 by University of Central Florida researcher Annette Khaled has been licensed to SEVA Therapeutics for further development and clinical testing in metastatic breast cancer. The peptide disrupts the folding mechanism inside cancer cells but does not harm healthy cells.
A genomewide association study confirmed 17 loci associated with basal cell carcinoma risk and identified 14 new loci. The findings, published in Nature Communications, were based on more than 17,000 cases and nearly 290,000 controls from the Nurses' Health Study and Health Professionals Follow-Up Study and direct-to-consumer genetic testing company 23andMe.
A digestible, nontoxic battery that can power 5-milliwatt ingestible medical devices for up to 18 hours has been unveiled by a team of Carnegie Mellon University researchers at the annual meeting of the American Chemical Society. The team, which is seeking to partner with companies to commercialize the product, created the battery primarily from melanin pigments and encapsulated it in a 3D-printed gelatin shell.
Startup biotechnology companies often falter in designing and executing strategies to move a product through clinical evaluation and clinical trials, writes Halloran Consulting President and CEO Laurie Halloran. She describes five common pitfalls, starting with a failure to recognize that the FDA and other regulatory bodies -- not investors, physicians or patients -- are a startup's first customers.
The Bayer Hemophilia Awards Program has awarded six grants to researchers at the University of Florida Cancer & Genetics Research Center, the Georgia Institute of Technology, the Boston VA Research Institute, the University of Mississippi and the University of Pennsylvania for education and research on the subjects of hemophilia and bleeding disorders.
A Clemson University researcher has been awarded a $6 million grant from the National Science Foundation to study treatments for brain disorders using nanoparticles. Stephen Foulger plans to develop coated nanoparticles that will travel to light-sensitive areas of the brain, where they'll be triggered by X-rays to treat such disorders as addiction and depression.
The US Patent and Trademark Office is challenging participants in its Cancer Moonshot Challenge to come up with ways to link data from the PTO's new Developer Hub portal to economy- and research grant-related data sets. The goal is to better use intellectual property data and combine it with other data to support cancer research and the development of new treatments, PTO Chief of Staff Vikrum Aiyer and Senior Adviser Thomas Beach wrote in a blog post.
A final guidance has been issued by the FDA to outline the factors the agency takes into consideration when making benefit-risk determinations during the medical device premarket review process. Another guidance has been finalized by the agency to outline the concepts stakeholders must consider when deciding to collect patient preference information, as well as the agency's recommendations for using such data in labeling some devices.
Experts attending the Precision Medicine Leaders Summit outlined a path toward using genetic and phenotypic data to redefine disease, develop new therapies and improve human health while controlling medical spending and improving health care quality. Discussions underscored that collaboration between and within the government and the scientific community is key.
FasterCures is an action tank that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.
1101 New York Avenue, NW
Washington, DC 20005
(202) 336-8900 |